A standard cholesterol panel gives you six or seven numbers, and most of them get ignored or misunderstood. Your doctor really acts on only a couple, and one of the most useful, non-HDL cholesterol, often gets overlooked entirely. For most decisions, LDL and non-HDL do the heavy lifting. HDL, total cholesterol, and ratios are usually context.
Quick map: what each lipid number is good for
| Marker | Best use | Common trap |
|---|---|---|
| LDL-C | Main treatment target for artery risk | Can undercount risk when triglycerides are high or LDL is very low |
| Non-HDL-C | Built-in estimate of all atherogenic cholesterol | Often ignored even though it is on the panel |
| Triglycerides | Metabolic signal for insulin resistance, visceral fat, and pancreatitis risk when very high | Treating the number without asking why it is high |
| HDL-C | Background risk context | Trying to raise HDL as if it were a treatment goal |
| Total cholesterol and ratios | Crude context, including total/HDL and triglyceride/HDL ratios | Acting on them instead of LDL, non-HDL, and overall risk |
| ApoB | Particle count when LDL may be misleading | Ordering it when LDL and risk are already clear |
| Lp(a) | Inherited risk you test once | Expecting diet, exercise, or statins to lower it much |
LDL: the one that drives the disease (with an asterisk)
On the lipid profile, LDL cholesterol is usually the number that matters most, because LDL particles directly cause artery disease, not just travel alongside it. Lower it and you lower heart attacks, reliably: every 39 mg/dL drop cuts major cardiovascular events by around 20 percent, down to very low levels.1 The asterisk: on a standard panel, LDL-C is usually calculated from the other values, not measured directly. The formula gets unreliable when triglycerides are high or LDL is very low, exactly the situations where it can undercount risk.2 That is one reason the single LDL number is not always the whole story.
Is HDL really “good cholesterol”?
Sort of, but the label causes confusion. HDL particles do help move cholesterol out of artery-wall cells and back toward the liver. That part is real. The problem is that the HDL number on your lab report measures how much cholesterol is riding inside HDL particles, not how well those particles work.
That is why HDL can look protective in population studies but still fail as a treatment target. Drugs that raise HDL (niacin, the CETP inhibitors) all flopped; none of them cut cardiovascular events.4 And very high HDL is not protective. Above roughly 80 mg/dL in men, the risk curve actually turns back upward.3 So treat HDL as background context, not a goal to chase. There is no useful “raise your HDL” prescription.
Triglycerides and non-HDL: the metabolic story
Triglycerides mostly tell you about your metabolism. High triglycerides (over 150) often travel with insulin resistance, visceral fat, higher blood sugar, and fatty liver risk.5 Very high triglycerides (over 500) can inflame the pancreas.8 You usually do not need to fast for a lipid panel anymore, but if triglycerides are very high, the next step is often a repeat fasting panel.6
The useful companion number is non-HDL cholesterol, which is simply your total cholesterol minus HDL. It captures every artery-clogging particle in one figure, predicts risk better than LDL-C,7 costs nothing extra, and does not require fasting. The 2026 ACC/AHA guideline now puts a non-HDL goal next to every LDL goal.6 If your triglycerides run high while your LDL looks fine, non-HDL is where the mismatch often shows up.
Total cholesterol, ratios, ApoB, and Lp(a)
Total cholesterol on its own is too blunt to act on; it lumps the good, the bad, and the in-between into one figure. The common ratios, total cholesterol divided by HDL, or triglycerides divided by HDL, can add some prognostic color. They are not treatment targets, and they should not outrank LDL, non-HDL, ApoB, or your overall risk.
Two add-ons are still worth knowing about. ApoB directly counts your atherogenic particles and catches risk the cholesterol numbers miss.7 Lipoprotein(a), an inherited risk factor, is worth measuring once in your life.6 Both have their own deeper write-ups.
Where a lipid panel can mislead
The lab report’s “normal” range means typical for the population, not optimal for your arteries; the levels linked to the least heart disease are lower than the reference range implies. And the fancy add-ons a wellness clinic might push, like LDL particle-size testing by NMR, are not recommended6; non-HDL and ApoB already capture what you need. Newer guidance (in 2026) is also pushing risk assessment earlier, into your 30s, treating the panel as a measure of cumulative exposure rather than a one-time snapshot,6 which is a shift worth its own discussion.
Read your lipid panel: LDL and non-HDL first, the rest as context
When your panel comes back, look at LDL and non-HDL first; those are the two your treatment actually hinges on. If your triglycerides are up, trust non-HDL over LDL. If either LDL or non-HDL is above your goal, ask your doctor what risk category you are in and what would actually lower artery-forming particles, not what would make HDL look prettier. Do not lose sleep over total cholesterol or ratios. And remember that the reference range is a population average, not a finish line: what counts as a good number for you depends on your overall risk.